---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-274378"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:24:28.192222+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Palvella Q3 net loss $11.3M; cash $63.6M; Phase 2/3 readouts on track for Dec 2025 and Q1 2026

## Summary
- Net loss per share $1.03 (basic/diluted) vs $3.94 a year ago; R&D expense rose to $6.5M.
- Cash & equivalents $63.6M, expected to fund operations into H2 2027.
- Phase 2 TOIVA (cutaneous VMs) top-line results expected mid-December 2025.
- Phase 3 SELVA (microcystic LMs) top-line results expected Q1 2026.
- Expanded pipeline: angiokeratomas and QTORIN pitavastatin for DSAP; Phase 2 start H2 2026; David Osborne appointed CINO.

## SEC filing metadata
- accession: 0001193125-25-274378
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000119312525274378/0001193125-25-274378-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000119312525274378/pvla-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-274378
- JSON: https://secwatch.observer/filing/0001193125-25-274378.json
- Plain text: https://secwatch.observer/filing/0001193125-25-274378.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.